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Eradicating the latent HIV-1 reservoir
represents a challenge. Pache et al.
identify BIRC2/cIAP1 as a negative
regulator of early HIV-1 transcription.
Antagonism of BIRC2 by Smac mimetics,
a class of molecules currently under
evaluation for cancer, enhances HIV-1
transcription, reactivates latent virus, and
synergizes with HDAC inhibitors to
reverse latency.
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Combination antiretroviral therapy (ART) is able to
suppress HIV-1 replication to undetectable levels.
However, the persistence of latent viral reservoirs
allows for a rebound of viral load upon cessation of
therapy. Thus, therapeutic strategies to eradicate
the viral latent reservoir are critically needed. Em-
ploying a targeted RNAi screen, we identified the
ubiquitin ligase BIRC2 (cIAP1), a repressor of the
noncanonical NF-kB pathway, as a potent negative
regulator of LTR-dependent HIV-1 transcription. De-
pletion of BIRC2 through treatment with small mole-
cule antagonists known as Smacmimetics enhanced
HIV-1 transcription, leading to a reversal of latency
in a JLat latency model system. Critically, treat-
ment of resting CD4+ T cells isolated from ART-sup-
pressed patients with the histone deacetylase in-
hibitor (HDACi) panobinostat together with Smac
mimetics resulted in synergistic activation of the
latent reservoir. These data implicate Smacmimetics
as useful agents for shock-and-kill strategies to elim-
inate the latent HIV reservoir.
INTRODUCTION
HIV-1 latency is a state of nonproductive infection in which tran-
scription of viral genes is repressed, likely through the concerted
activities of multiple host pathways. While HIV-1 replication canCell Host &be reduced to undetectable levels using combination antiretrovi-
ral therapy (ART), latently infected viral reservoirs can persist for
decades (reviewed in Margolis, 2010). In well-suppressed pa-
tients, cessation of therapy typically leads to increased viremia
within 3–4 weeks, and thus HIV-1-infected individuals must
remain on ART throughout their lifetimes. Given the expense
and toxicities associated with long-term therapies, pharmaco-
logical strategies designed to eradicate the viral latent reser-
voir represent a critical unmet need. Current ‘‘shock and kill’’
approaches seek to purge this reservoir by treating patients
with therapeutics that activate latently infected cells, which
are thought to be subsequently eliminated due to viral cyto-
pathic effects or the immune response of the host (Xing and Sil-
iciano, 2013). However, the optimal means for reactivating latent
HIV-1 is at present unclear.
The establishment and maintenance of HIV-1 latency is con-
trolled by a multitude of cis- and trans-acting mechanisms
that include factors affecting the local chromatin environment
or the levels of specific transcription factors, respectively (Dona-
hue and Wainberg, 2013). Histone deacetylase inhibitors
(HDACis) are known as general activators of transcription and
have also been shown to reverse latency in multiple model sys-
tems (Margolis, 2011). Recent studies have indicated that most
HDACi are unable to reactivate latent HIV-1 ex vivo with robust
and consistent efficacies (Bullen et al., 2014; Wei et al., 2014).
Therefore, it is presently not clear if treatment with an HDACi
as single agent is sufficient to effectively reactivate latent HIV-1.
In addition to the local chromatin environment, specific tran-
scription factors are also critical regulators of viral latency. A sig-
nificant body of evidence indicates that NF-kB signaling plays
an important role in the reactivation of latent HIV-1, implicating
its regulation as an important therapeutic strategy for latencyMicrobe 18, 345–353, September 9, 2015 ª2015 Elsevier Inc. 345
Figure 1. Identification of Cellular Factors Impeding HIV-1 Replication through Targeted siRNA Screening
(A) Candidate genes derived from genome-wide screening data sets were evaluated in a siRNA screen in HEK293T cells infected with HIV-1(VSVg). Twenty-four
screening hits were selected for further validation, with 12 of these candidate genes being successfully validated using a set of more rigorous criteria (see text).
(B) Heatmap showing the activity of siRNAs targeting 139 genes identified in a siRNA screen described in (A). See also Table S1.
(C) Enrichment analysis of biological processes among screening hits. Shown are selected gene ontology terms enriched with p < 0.05 following Benjamini-
Hochberg correction.
(legend continued on next page)
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reversal (Nabel and Baltimore, 1987; Williams et al., 2006). In
fact, among the most efficient proposed latency reversing
agents (LRAs) are protein kinase C (PKC) activators, including
bryostatin, ingenol, and phorbol esters such as PMA and pros-
tratin. These compounds activate the canonical NF-kB pathway
and have been found to reverse latency in cellular models and
CD4+ T cells from HIV-1-infected patients (Bullen et al., 2014;
Spivak et al., 2015; Xing and Siliciano, 2013). However, clinical
uptake of these compounds has been complicated by concerns
about tumorigenesis and other toxicities, particularly due to un-
controlled cytokine release (Xing and Siliciano, 2013).
Toxicity associated with agonists of canonical NF-kB sig-
naling, which is governed by TAK1/IKK signalosome activation,
is in large part due to the acute, short-lived transcriptional activa-
tion that is initiated after pathway activation, resulting in a broad
inflammatory response. Although abundant evidence implicates
canonical NF-kB signaling in the control of HIV-1 transcription
and latency, the influence of the noncanonical NF-kB pathway
in regulating HIV-1 transcription and latency has not been estab-
lished. In contrast to canonical NF-kB signaling, the noncanoni-
cal NF-kB pathway is characterized by a slower onset, long-last-
ing transcriptional response, and higher functional selectivity,
restricting its impact to a limited number of cellular processes
and cell types (reviewed in Sun, 2012). The activation of the non-
canonical NF-kB pathway occurs only through a specific subset
of tumor necrosis factor receptors (TNFRs), including lympho-
toxin beta receptor (LTbR) and CD40. In the absence of stimula-
tion, a complex of BIRC2 (cIAP1), BIRC3 (cIAP2), TRAF2, and
TRAF3 constitutively degrades NF-kB-inducing kinase (NIK).
Upon receptor activation, BIRC2 and BIRC3 promote the ubiqui-
tination and subsequent degradation of TRAF3, thereby permit-
ting an accumulation of NIK. In turn, NIK activation results in
the phosphorylation IKKa, leading to the subsequent proteo-
lytic processing of p100 to p52. p52 forms a heterodimer with
the RELB transcription factor and translocates to the nucleus,
inducing the expression of target genes. Crosstalk between
various canonical and noncanonical NF-kB signaling compo-
nents, resulting in both positive and negative pathway crossre-
gulation, is considered to be a critical feature in shaping biolog-
ical responses to a variety of extracellular stimuli (Basak et al.,
2007; Shih et al., 2011; Zarnegar et al., 2008).
Here, using targeted RNAi screening, we have identified
BIRC2, a repressor of the noncanonical NF-kB pathway, as a
potent regulator of HIV-1 transcription and as a therapeutic
target for the reversal of latency. Small molecule antagonists of
BIRC2, in combination with HDAC inhibitors, activated latent
proviruses in both cell line-based models of latency and in
primary CD4+ T cells isolated from ART-suppressed HIV-1-in-
fected patients. The results of this study indicate that the phar-
macological activation of the noncanonical NF-kB pathway
can be used as a component of a combinatorial regimen to
reactivate latent HIV-1, while potentially limiting toxicity risks
associated with systemic activation of NF-kB signaling by PKC
agonists.(D) Mapping of 12 validated genes to the HIV-1 replication cycle. HEK293T cells w
HIV-1(VSVg), the levels of HIV-1 total DNA, integrated provirus, and HIV-1 mRNA
gene knockdown levels, and cell viability upon target gene knockdown. All values
least three biological replicates. * indicates statistical significance as determined
Cell Host &RESULTS
Identification of Host Cell Factors that Impede Early
Stages of HIV-1 Replication
Using a genome-wide siRNA-based loss-of-function screen, we
previously identified 295 cellular genes encoding proteins that
support viral replication (Ko¨nig et al., 2008). To elucidate cellular
factors that interfere with HIV-1 replication, we have reanalyzed
this data set along with additional published and unpublished
data sets from genome-wide gain- or loss-of-function analyses
(Agarwal et al., 2006; Nguyen et al., 2007), identifying 651 genes
that were predicted to have a likelihood of impeding HIV-1 repli-
cation. Using a triaging strategy based on results froman arrayed
siRNA loss-of-function screen (Figure 1A), we evaluated the role
of these factors in the early stages of HIV-1 replication, including
LTR-mediated transcription. Four distinct siRNAs targeting each
candidate gene were evaluated in HEK293T cells infected with a
single-cycle, VSV-G-pseudotyped, HIV-1 reporter virus (HIV-1
[VSVg]) in the absence of interferon. Results from this analysis
led to the identification of 139 host factors that, when depleted,
enhanced viral infection by 50% or more compared to the nega-
tive control with at least two independent siRNAs (Figure 1B; see
Table S1 available online). Proteins involved in cell cycle regula-
tion, ubiquitination, apoptosis, and DNA replication were found
to be enriched in the set of 139 genes (Figure 1C), including
CYLD, a gene we recently reported to regulate LTR-dependent
transcription (Manganaro et al., 2014).
Cellular Factors that Limit Viral Transcription
We next performed a more rigorous validation study on 24 of
the 139 factors that, when depleted, promoted HIV-1 infection. A
gene was considered validated if at least two sequence-indepen-
dent siRNAs enhanced expression of the luciferase reporter gene
by 2.5-fold or more. We excluded genes where RNAi depletion
altered cell viability >35% or the mRNA expression level of the
targeted gene was not reduced by >35%. We found that 12 of
the 24 selected genes met these more rigorous criteria (Table
S2), including factors involved in apoptotic signaling (BIRC2,
CASP8AP2), ubiquitin-mediated proteolysis (CUL3, RNF7), and
antigen presentation (HLA-B). Only one factor induced G2/M cell
cycle arrest upon depletion (Figure S1A) (Groschel and Bushman,
2005; Gummuluru and Emerman, 1999). We next used previously
established assays to identify the specific steps of the early viral
replicationcycle thatwere influencedby these12host factors (Fig-
ures 1D and S1B). Knockdown of a subset of genes, including
CASP8AP2, CUL3, and COL6A1, led to a modest increase in the
levels of viral DNA and integrated provirus. Depletion of eight
genes enhanced levels of HIV-1 transcription without significantly
affecting levels of integrated provirus, among these the ubiquitin
ligaseBIRC2, a critical regulator of noncanonical NF-kB signaling.
BIRC2 Antagonist Treatment Enhances HIV-1 Infection
Smac mimetics are synthetic molecules that mimic a critical
tetrapeptide sequence from the second mitochondria-derivedere treated with siRNAs targeting the indicated genes. Following infection with
were determined by qPCR. Also shown are luciferase expression levels, target
are normalized to nontargeting control siRNAs and represent mean ± SD of at
by Holm-Sidak t test (alpha = 0.05).
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activator of caspase (Smac/Diablo). Smac binds to the baculovi-
ral IAP repeat (BIR) domains that are common to the eight mem-
bers of the inhibitor of apoptosis (IAP) family of proteins, which
includes XIAP, BIRC2, and BIRC3 (Fulda and Vucic, 2012). The
IAP proteins differ in function, and only BIRC2 and BIRC3 are
known regulators of noncanonical NF-kB signaling. Most Smac
mimetics directly compete with caspases for XIAP binding, but
also can allosterically activate the E3 ubiquitin ligase activity of
BIRC2 and BIRC3, leading to autoubiquitination and subsequent
degradation of these proteins. Primarily through their ability to
bind XIAP, Smac mimetics can elicit proapoptotic activities,
and thus have been developed to treat both solid and hemato-
logical cancers (Bai et al., 2014). We have previously described
the small molecule SBI-0637142 as a potent Smac mimetic
that preferentially targets BIRC2 (Finlay et al., 2014; Vamos
et al., 2013). Here, we find that treating HEK293T cells with
SBI-0637142 resulted in enhanced HIV-1 replication, similar to
the effects of siRNA-mediated BIRC2 knockdown. This activity
was concordant with the depletion of BIRC2 protein, while no
change in BIRC3 protein levels was observed (Figure 2A).
Furthermore, the loss of BIRC2 led to the accumulation of NIK,
indicating that treatment with the Smac mimetic resulted in the
activation of the noncanonical NF-kB pathway.
Next, CD4+ T cells isolated from six healthy donors were
treated with SBI-0637142 or LCL161, a second Smac mimetic
that has been evaluated in phase I/II clinical trials for patients
with advanced solid tumors (Bai et al., 2014; Infante et al.,
2014). Treatment with SBI-0637142 and LCL161 both enhanced
expression of the viral luciferase reporter gene 2- to 10-fold rela-
tive to the DMSO control upon HIV-1(VSVg) infection, without
inducing significant cytotoxicity (Figure 2B). As expected, both
compounds decreased BIRC2 protein levels and resulted in
the stabilization of NIK.
BIRC2 Affects Viral Transcription via NF-kB-Dependent
Signaling
The HIV LTR contains two copies of an NF-kB enhancer ele-
ment known to bind the RELA:p50 heterodimer in response to
the activation of canonical NF-kB signaling (Nabel and Balti-
more, 1987). Observations using in vitro biochemical systems
indicate that the noncanonical RELB:p52 heterodimers also
can bind these sequences (Britanova et al., 2008; Fusco et al.,
2009). Since knockdown of BIRC2, a negative regulator of
noncanonical NF-kB signaling, increased expression of HIV-1
mRNA (Figure 2C), we hypothesized that the effects of BIRC2
depletion were mediated through NIK-dependent activation
of NF-kB signaling and subsequent interaction of transcription
factors with the NF-kB binding sites in the HIV-1 LTR. To test
this hypothesis, siRNA-treated HEK293T cells were infected
with VSV-G-pseudotyped HIV-1 that had either mutant or native
NF-kB binding sites in the LTR (Figure 2D). We found that
knocking down BIRC2 by siRNA treatment had little effect on
HIV-1 expression when the NF-kB binding sites were inacti-
vated by mutation. Consistent with these findings, mutating
the NF-kB binding sites in the LTR abrogated the effects of
SBI-0637142 upon HIV-1 transcription (Figure 2E). Moreover,
overexpression of LTbR or CD40, both members of the TNF
receptor superfamily that stimulate the noncanonical NF-kB
pathway, increased the expression of the viral luciferase re-348 Cell Host & Microbe 18, 345–353, September 9, 2015 ª2015 Elsporter gene upon HIV-1(VSVg) infection (Figure 2F). Taken
together, these results indicate that BIRC2 affects HIV-1 LTR-
dependent transcription through regulation of NF-kB signaling.
BIRC2 Antagonists Act as Latency-Reversing Agents
Since transcriptional regulation has been implicated in the main-
tenance of HIV-1 latency, we investigated whether antagonism
of BIRC2 can lead to reactivation of latent infection. Treating
the latently infected Jurkat cell line JLat 10.6 with SBI-0637142
led to a dose-dependent reactivation of the provirus with negli-
gible effects on cell viability (Figure 3A). The extent of viral la-
tency reversal was found to be proportional to the depletion of
BIRC2 and the activation of the noncanonical NF-kB pathway,
as indicated by the accumulation of NIK and the processing of
p100 to p52. Importantly, we found that three additional Smac
mimetics, which have previously been evaluated in clinical trials
(Bai et al., 2014), also showed LRA activity in a Jurkat latency
model (Figure S2A). This indicates that latency reversal is not
limited to individual compounds, but that Smac mimetics more
generally represent a novel class of LRAs.
We also monitored the activation kinetics of NF-kB signaling
upon treatment with SBI-0637142. After exposing JLat cells
to the Smac mimetic, we observed degradation of BIRC2
within 15 min, followed by the stabilization of NIK after 1 hr,
and subsequent increases of the p52 protein levels (Figure 3B),
indicating the activation of the noncanonical NF-kB pathway.
However, we did not observe a reduction in the levels of IkBa
bywestern blot, which is a hallmark of canonical NF-kB signaling
activation (Figure 3B). The kinetics of viral RNA (vRNA) expres-
sion following the treatment of latently infected Jurkat cells
with SBI-0637142 correlated with the observed induction of
NIK-dependent NF-kB signaling (Figure S2B).
To determine whether the observed activation of HIV tran-
scription by Smac mimetics is solely mediated through the NIK
signaling axis, we generated a NIK knockout in the latently in-
fected 2D10 cell line using a CRIPSR-based approach (Fig-
ure S2C). The loss of NIK abrogated the reactivation of latent
HIV-1 through SBI-0637142 treatment, while not impinging
upon the activity of PKC agonist bryostatin, an activator of ca-
nonical NF-kB signaling (Figure 3C). To further investigate the
mechanism by which induction of the noncanonical pathway re-
sults in the LTR-dependent transcriptional activation of HIV-1,
we have analyzed the nuclear translocation of NF-kB transcrip-
tion factors upon treatment of CD4+ T cells with SBI-0637142
(Figure 3D). We found that both p52 and RELB translocate to
the nucleus following BIRC2 depletion and NIK accumulation.
In addition, low levels of RELA translocation were detected as
well. Importantly, the translocation of RELA paralleled the de-
layed kinetics of NF-kB activation via the noncanonical NIK-
p100 signaling axis, in contrast to the rapid nuclear accumulation
resulting from TNFa stimulation. This suggests that activation of
RELA was likely due to pathway crosstalk initiated after the in-
duction of noncanonical signaling.
To further investigate this result, we used chromatin immuno-
precipitation (ChIP) to assess the physical occupancy of the
HIV-1 LTR by NF-kB transcription factors after induction of
noncanonical signaling (Figure 3E). We find that Smac mimetic
treatment leads to an association of RELB with the viral LTR,
suggesting that noncanonical NF-kB transcription factors canevier Inc.
Figure 2. Effects of BIRC2 Depletion on HIV-1 Transcription in HEK293T Cells and Primary Cells
(A) HEK293T cells were treated with the BIRC2 antagonist SBI-0637142 at the indicated concentrations and infected with HIV-1(VSVg) for 24 hr. Levels of
infection were evaluated by measuring luciferase reporter activity. Lysate of SBI-0637142-treated cells was evaluated for BIRC2 and NIK protein levels by
western blot.
(B) Primary activated CD4+ T cells isolated from six healthy donors were treated with SBI-0637142 or LCL161 at the indicated concentrations for 24 hr. Cells were
subsequently infected with HIV-1(VSVg) for 48 hr before analysis of luciferase reporter activity. Cell viability was evaluated bymeasuring cellular ATP levels. Each
data point indicatesmean of biological triplicates from a single donor. Lines indicatemean of six donors. BIRC2 depletion andNIK accumulation were analyzed by
western blot.
(C) HIV-1(VSVg)-infected HEK293T cells treated with siRNAs targeting BIRC2 were analyzed for levels of total HIV-1 DNA, integrated provirus, and HIV-1 mRNA
by qPCR. Luciferase expression levels were evaluated in parallel. All values are normalized to nontargeting control siRNAs. BIRC2 and NIK protein expression
levels upon siRNA treatment were analyzed by western blot.
(D) siRNA-treated HEK293T cells were infected with VSVg-pseudotyped HIV-1 (WT) or a virusmutant lacking functional NF-kB binding sites (DNFkB). Viral mRNA
was measured by qPCR 24 hr after infection, and values were normalized to nontargeting control siRNAs. CASP8AP2-targeting siRNAs are shown as control.
(E) HEK293T cells were treated with 1 mM SBI-0637142 and infected for 24 hr with VSVg-pseudotyped HIV-1 containing either a functional or mutated NF-kB
binding site in the viral LTR. HIV-1 mRNA levels were quantified by qPCR and normalized to samples from cells treated with 5 mM nevirapine (NVP).
(F) HEK293T cells transfected with vectors expressing CD40 or LTbR were subsequently infected with HIV-1(VSVg) for 24 hr. Viral infection was quantified by
measuring expression of the viral encoded luciferase reporter and normalized to cells transfected with an empty vector as negative control.
All data are represented asmean ± SD of three biological replicates (A, B, andD) or asmean ± SEMof at least three independent experiments (E–G). p valueswere
calculated using an unpaired t test with *p < 0.05 and **p < 0.01.
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Figure 3. Smac Mimetic-Mediated BIRC2 Depletion Leads to the Reactivation of Latent HIV-1 in JLat Cells
(A) JLat 10.6 cellswere treatedwith increasing amountsofSBI-0637142 for 36hr.Reversalof latencywasdeterminedbyFACSanalysis ofGPFexpression.Depletion
of BIRC2, accumulation of NIK, and processing of p100 to p52 were analyzed by western blot. FACS data are represented as mean ± SEM of three experiments.
(B) Kinetics of NF-kBactivation upon treatment of JLat 10.6 cells with 1 mMSBI-0637142were assessed bywestern blot. Treatment with 10 ng/ml TNFa served as
positive control for canonical NF-kB pathway activation.
(C) 2D10 cells and cloneswith a knockout ofNIK orNFKB2were incubatedwith 1 mMSBI-0637142 or 30 nMbryostatin for 36 hr. GFP expression was analyzed by
FACS. Data are represented as mean ± SD of three biological replicates.
(D) CD4+ T cells from healthy donors were treated with 1 mM SBI-0637142 or 10 ng/ml TNFa. Cytoplasmic (CE) and nuclear (NE) extracts were analyzed by
western blot. HSP90 and PARP1 served as control for cytoplasmic and nuclear proteins, respectively.
(E) 2D10 cells were treated with 1 mM SBI-0637142 for 9 hr prior to ChIP analysis using antibodies against RELA, RELB, or IgG as control. RELA- and RELB-
specific association with the HIV-1 LTR and the IkBa gene promoter region, or an intergenic region upstream of the PABPC1 gene not known to contain NF-kB
binding sites as negative control, was analyzed by qPCRusing specific primers and is shown as fold enrichment over IgG control. Data are represented asmean ±
SEM of at least three experiments. *p < 0.05, **p < 0.01, ***p < 0.001, determined by unpaired t test.
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Figure 4. Combined Treatment with Smac Mimetics and HDAC In-
hibitors Reverses HIV-1 Latency in Jurkat-Based Latency Models
and Patient-Derived Resting CD4+ T Cells
(A) Latently infected Jurkat cell lines were treated with increasing amounts of
SBI-0637142 alone or in combination with panobinostat or vorinostat. JLat
10.6 and 5A8 cells were treated with 10 nM panobinostat and 500 nM vor-
inostat, where indicated. 2D10 cells were treated with 5 nM panobinostat and
250 nM vorinostat. GFP expression was evaluated after 36 hr by FACS. Data
are represented as mean ± SD of three biological replicates.
(B) Resting CD4+ T cells from HIV-1-infected patients under ART were treated
with 100 nM panobinostat, 10 mM LCL161, 10 mM SBI-0637142, or a combi-
nation thereof for 48 hr. Viral production was subsequently evaluated by
detection of viral mRNA in cell supernatants using qPCR. Data are represented
asmean ± SEMof four donors. Significance of treatments was evaluated using
a ratio paired t test. *p < 0.05.directly influence HIV transcription. Moreover, we also detected
binding of RELA to the HIV LTR, implicating a concerted action of
both canonical and noncanonical transcription factors in HIV-1
activation upon Smac mimetic treatment. TNFa treatment, by
contrast, resulted in RELA binding to the LTR but did not lead
to a significant interaction with RELB (Figure S2D). To discern
the functional contribution of the noncanonical RELB:p52 heter-
odimer to LRA activity after Smacmimetic treatment, we created
a cell line with a knockout of the NFKB2 gene, resulting in a loss
of p100 expression (Figure S2E). In the absence of p100, andCell Host &thereby p52, the reversal of HIV latency by Smac mimetics
was reduced by75% (Figure 3C). Taken together, these results
indicate that the LRA activity of Smac mimetics is solely initiated
through the NIK-dependent noncanonical NF-kB signaling
pathway. Induction of this pathway activates both the RELB:p52
heterodimer and, to a lesser extent, the RELA:p50 heterodimer,
and results in the activation of LTR-dependent transcription that
is primarily, but not exclusively, regulated by the noncanonical
NF-kB transcription factor heterodimer.
BIRC2 Antagonist Treatment Acts Synergistically with
HDAC Inhibitors to Reverse HIV-1 Latency
LRAs, such as PKC activators and HDAC inhibitors, have been
shown to activate latent provirus synergistically (Burnett et al.,
2010; Laird et al., 2015). We thus investigated the effects of
Smac mimetics together with HDACis in three Jurkat-derived la-
tency models—JLat 10.6, 2D10, and 5A8 cells (Figures 4A and
S3A) (Pearson et al., 2008; Sakane et al., 2011). In each of the
three cell lines tested, the combination of the Smac mimetic
SBI-0637142, with either of the HDAC inhibitors panobinostat
or vorinostat, reactivated latent provirus synergistically (Fig-
ure S3B). Although less potent, the Smac mimetic LCL161
showed similar synergy.
We next evaluated Smac mimetics for their ability to reverse
latency in resting CD4+ T cells collected from HIV-1-infected
patients undergoing ART (n = 4). Cells were treated with
SBI-0637142 or LCL161 alone, or in combination with the
HDACi panobinostat, and release of viral genomic RNA to
the supernatant was measured by the recently described
REVEAL (rapid ex vivo evaluation of antilatency) assay (Spivak
et al., 2015). While none of the small molecules were found
to activate latent provirus after 48 hr when used individually,
both LCL161 and SBI-0637142 in combination with panobi-
nostat were found to reactivate latent HIV-1 at levels compa-
rable to those achieved upon treatment with antibodies
against CD3 and CD28 (Figure 4B). Importantly, these results
reach statistical significance (p < 0.05) for SBI-0637142 and
CD3/CD28 antibody treatment, and no significant activation
of resting CD4+ T cells was observed upon treatment with
SBI-0637142 (Figure S3C).
DISCUSSION
Using a targeted siRNA screen, we identified BIRC2, a negative
regulator of noncanonical NF-kB signaling, as a regulator of
viral transcription. Critically, we observed that induction of non-
canonical signaling results in both RELA:p50 and RELB:p52 het-
erodimeric transcription factors binding to the HIV-1 LTR, with
genetic loss-of-function studies indicating that the transcrip-
tional activation by RELB:p52 is the predominant regulator of
this activity. Taken together, these results support an unappreci-
ated role for the noncanonical NF-kB signaling machinery, and
specifically RELB:p52, in the regulation of HIV-1 LTR-dependent
transcription.
There have been considerable efforts focused on understand-
ing the molecular basis of HIV-1 latency and devising pharmaco-
logical strategies to activate the latent provirus. Ideally, an LRA
should only target cell types that are latently infected so as to
avoid toxicity or widespread immune activation. In contrast toMicrobe 18, 345–353, September 9, 2015 ª2015 Elsevier Inc. 351
strategies targeting canonical NF-kB signaling, it may be prefer-
able to target components of the noncanonical NF-kB pathway,
as it is active in a more restricted set of cell lineages. Smac
mimetics are considered a promising new class of cancer thera-
peutics that are well tolerated in vivo, and primarily through
their antagonism of XIAP, they promote apoptosis in tumor
cells, while normal tissue remains unaffected (Fulda and Vucic,
2012). Many Smac mimetics can also trigger the noncanonical
NF-kB signaling pathway through the depletion of BIRC2 or
BIRC3. Although constitutive activation of the noncanonical
NF-kB pathway through somatic mutations in mice has been
associated with hematogenous malignancies including B cell
lymphomas (Keats et al., 2007), proposed latency-reversing
‘‘shock and kill’’ approaches entail acute treatment regimens,
largely mitigating these risks associated with chronic activation.
In fact, six Smac mimetics, including LCL161, have been evalu-
ated in clinical trials and have favorable safety and pharma-
cokinetic/pharmacodynamic (PK/PD) profiles (Bai et al., 2014).
Unlike broadly acting Smac mimetics that target multiple pro-
teins of the IAP family including the caspase inhibitor XIAP,
certain compounds, such as SBI-0637142, preferentially target
BIRC2 or BIRC3, the only known regulators of noncanonical
NF-kB signaling among the IAP proteins (Finlay et al., 2014).
Future studies will be required to investigate whether the
observed increased potency of SBI-0637142 as an LRA may
be related to its selectivity profile.
Many current strategies for reactivating latent HIV-1 focus
on the use of PKC agonists to stimulate canonical NF-kB
signaling. Due to toxicity risks, safety concerns have dampened
enthusiasm for the use of these canonical NF-kB activators as
LRAs (Morgan et al., 2012). HDACi have also shown promise
as LRAs, with multiple compounds being evaluated in clinical
trials (Rasmussen et al., 2013). Although HDACis increase intra-
cellular levels of HIV-1 mRNA both in vitro and in vivo, the level
of viral outgrowth induced by these compounds is likely insuffi-
cient to purge the viral reservoir (Bullen et al., 2014; Wei et al.,
2014). Therefore, it is expected that a safe and effective drug
regimen to reverse HIV-1 latency will require the combination
of multiple agents (Xing and Siliciano, 2013), much like ART.
Some HDACi have been shown to synergize with different clas-
ses of LRAs including PKC agonists (Laird et al., 2015), indi-
cating that combinatorial use could increase efficacy while
reducing required dosage. Consistently, we see similar levels
of synergy between Smac mimetics and HDACi as levels re-
ported for combinatorial treatment with HDACi and PKC ago-
nists (Wong et al., 2014).
Given the scarcity of clinical data to date, the optimal strategy
for reversing HIV-1 latency in patients is far from certain. Our
results demonstrating that Smac mimetics, in conjunction with
the HDACi panobinostat, can reverse latency in patient-derived
resting CD4+ T cells suggest a promising clinical approach to-
ward the development of a ‘‘cure’’ for patients with HIV-1. Impor-
tantly, the established clinical safety and pharmacodynamic pro-
files of Smacmimetics should enable this class of small molecule
antagonists to be readily evaluated as a therapeutic strategy.
Taken together, these data indicate that rapid preclinical devel-
opment and clinical repositioning of Smac mimetics may help
provide a safe and effective combinatorial therapeutic regimen
to eradicate HIV-1.352 Cell Host & Microbe 18, 345–353, September 9, 2015 ª2015 ElsEXPERIMENTAL PROCEDURES
siRNA Transfections and Infection with HIV-1
siRNA transfections of HEK293T cells and infections with a single-cycle enve-
lope deleted, VSV-G-pseudotyped HIV-1 reporter virus (HIV-1[VSVg]), were
performed as previously described (Ko¨nig et al., 2008). Cells were infected
48 hr after siRNA transfection, and luciferase expression levels were deter-
mined 24 hr after infection. Mapping to viral replication cycle stages was
done by isolating mRNA and DNA from infected cells and quantifying proviral
DNA content, total HIV DNA, and HIV mRNA levels by qPCR. Cells infected
with VSV-G-pseudotyped HIV-1 containing either wild-type or mutant NF-kB
binding sites in the LTR (Bosque and Planelles, 2009) were analyzed by
measuring HIVmRNA levels by qPCR. Cell viability was analyzed using the AT-
Plite cell viability assay (Perkin Elmer).
HIV-1 Infection of Human CD4+ T Cells
Following isolation, CD4+ T cells from healthy donors were activated with
4 mg/ml phytohemagglutinin-P (PHA, Sigma) for 48 hr. Activated CD4+
T cells were treated with compounds for 24 hr prior to infection with HIV-
1(VSVg). Luciferase expression levels were normalized to mock-treated cells;
mean of DMSO-treated cells was defined as 1.
Jurkat HIV Latency Model
Latently infected Jurkat cells were treated with compounds and subsequently
analyzed for GFP expression by flow cytometry. Analytical cytometry was per-
formed in the Sanford BurnhamPrebys FlowCytometry Core. Cell viability was
determined using the ATPlite cell viability assay.
Chromatin Immunoprecipitation
2D10 cells were stimulated with 1 mM SBI-0637142 or DMSO for 9 hr prior to
ChIP using antibodies targeting RELA and RELB.
Treatment of Resting CD4+ T Cells from Aviremic HIV Patients
Resting CD4+ T cells isolated from aviremic HIV-1-infected patients on ART
were cultured in the presence or absence of reactivating compounds for
48 hr. Culture supernatants were analyzed by two-step qPCR using a primer
and probe set for conserved regions of the 30 LTR of HIV-1mRNA as previously
described (Spivak et al., 2015).
Please refer to the Supplemental Experimental Procedures for additional
information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article at http://
dx.doi.org/10.1016/j.chom.2015.08.009.
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